Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Azzoli

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Annals of Surgical Oncology|July 29, 2015
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical SurgeonChristopher G Azzoli
The Lancet. Oncology|September 2, 2006
Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stageChristopher G Azzoli
Journal of Surgical Oncology|November 18, 2006
Management of patients with resectable stage IIIA (N2) NSCLCChristopher G Azzoli
Nature Clinical Practice. Oncology|November 5, 2005
Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?Christopher G Azzoli
The Journal of Thoracic and Cardiovascular Surgery|May 24, 2020
Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?Christopher G Azzoli, Thomas Ng
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2019
Commentary: Chemotherapy for stage IB large cell neuroendocrine carcinomas of lung: Convention becomes convictionThomas Ng, Christopher G Azzoli
The Oncologist|November 27, 2013
Adjuvant therapy for a 3.9-cm adenocarcinoma of the lungRebecca Heist, Christopher G Azzoli
Rhode Island Medical Journal (2013)|April 3, 2020
Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that MatterChristopher Del Prete, Christopher G Azzoli
Translational Lung Cancer Research|November 9, 2017
Beyond <i>ALK</i> and <i>ROS1: RET, NTRK, EGFR</i> and <i>BRAF</i> gene rearrangements in non-small cell lung cancerAnna F Farago, Christopher G Azzoli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Reply to B. Jeremic et alAndrea Bezjak, Sarah Temin, Christopher G Azzoli
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Annals of Surgical Oncology|July 29, 2015
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical SurgeonChristopher G Azzoli
The Lancet. Oncology|September 2, 2006
Adjuvant chemotherapy for resected non-small-cell lung cancer--ANITA takes the stageChristopher G Azzoli
Journal of Surgical Oncology|November 18, 2006
Management of patients with resectable stage IIIA (N2) NSCLCChristopher G Azzoli
Nature Clinical Practice. Oncology|November 5, 2005
Can adjuvant chemotherapy improve survival in patients with early-stage, resected non-small-cell lung cancer?Christopher G Azzoli
The Journal of Thoracic and Cardiovascular Surgery|May 24, 2020
Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?Christopher G Azzoli, Thomas Ng
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2019
Commentary: Chemotherapy for stage IB large cell neuroendocrine carcinomas of lung: Convention becomes convictionThomas Ng, Christopher G Azzoli
The Oncologist|November 27, 2013
Adjuvant therapy for a 3.9-cm adenocarcinoma of the lungRebecca Heist, Christopher G Azzoli
Rhode Island Medical Journal (2013)|April 3, 2020
Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that MatterChristopher Del Prete, Christopher G Azzoli
Translational Lung Cancer Research|November 9, 2017
Beyond <i>ALK</i> and <i>ROS1: RET, NTRK, EGFR</i> and <i>BRAF</i> gene rearrangements in non-small cell lung cancerAnna F Farago, Christopher G Azzoli
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Reply to B. Jeremic et alAndrea Bezjak, Sarah Temin, Christopher G Azzoli
Pageof 10